Myriad Genetics lost a patent case in the Federal District Court for the Southern District of New York regarding isolated DNA sequences in seven of the 23 patents covering BRAC Analysis. A check on the NASDAQ shows what damage the loss of the patents did. Shares fell from 24.8 to 23.08 in one day, but has risen since. So it´s only a small dent in Myriads business.
The question is: if this is an indication of the value of the lost IP and if Myriad should drop an appeal when the value lost is so small?Â